Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Monday that its second quarter revenues rose 18 percent year over year.

For the three months ended June 30, the skin cancer diagnostics company reported revenues of $12.7 million, up from $10.7 million a year earlier, and beating the average Wall Street estimate of $8.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

Time magazine looks into how liquid biopsies are changing cancer care.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.